Literature DB >> 10554824

Fatal immune haemolysis due to a degradation product of ceftriaxone.

O Meyer1, H Hackstein, B Hoppe, F J Göbel, G Bein, A Salama.   

Abstract

A 16-year-old girl who was treated with ceftriaxone developed two intravascular haemolytic attacks that led to acute renal failure and death. The direct antiglobulin test was positive only for C3d, and no ceftriaxone-dependent antibodies were detectable. Her serum reacted strongly positive with red blood cells in the presence of ex vivo antigen related to ceftriaxone (urine samples from patients receiving the drug). This is the first reported case in which the causative antibodies appeared to be stimulated solely by a degradation product of ceftriaxone.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10554824     DOI: 10.1046/j.1365-2141.1999.01434.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Use of gel microcolumn assay for the detection of drug-induced positive direct antiglobulin tests.

Authors:  M C Z Novaretti; C R Sopeleti; P E Dorlhiac-Llacer; D A F Chamone
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

2.  Ceftriaxone-related hemolysis and acute renal failure.

Authors:  Erkan Demirkaya; Abdullah Avni Atay; Ugur Musabak; Ali Sengul; Faysal Gok
Journal:  Pediatr Nephrol       Date:  2006-02-21       Impact factor: 3.714

3.  Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre.

Authors:  Beate Mayer; Thilo Bartolmäs; Salih Yürek; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2015-09-09       Impact factor: 3.747

4.  Autoimmune Hemolytic Anemia - Fascinating from a Laboratory as well as from a Clinical Point of View.

Authors:  Hans-Gert Heuft; Axel Pruß
Journal:  Transfus Med Hemother       Date:  2015-09-27       Impact factor: 3.747

5.  Identification and Characterization of Hydrolytic Degradation Products of Cefditoren Pivoxil using LC and LC-MS/TOF.

Authors:  V T Gawande; K G Bothara; A Singh; A A Mahajan
Journal:  Indian J Pharm Sci       Date:  2015 Jan-Feb       Impact factor: 0.975

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.